INSM

Insmed Incorporated [INSM] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INSM Stock Summary

Top INSM Correlated Resources

INSM

Top 10 Correlated ETFs

INSM

Top 10 Correlated Stocks

INSM

In the News

INSM Financial details

Company Rating
-
Market Cap
4.05B
Income
-749.57M
Revenue
305.21M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
912
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-5.34
Forward P/E
-
PEG
-1.46
P/S
13.46
P/B
-12.07
P/C
-
P/FCF
-7.47
Quick Ratio
3.64
Current Ratio
4.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.34
EPS next Y
-
EPS next Q
-
EPS this Y
36.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
12.15%
Revenue last 5Y
17.47%
Revenue Q/Q
5.84%
EPS Q/Q
15.32%
-
-
-
-
SMA20
16.4%
SMA50
38.36%
SMA100
87.13%
Inst Own
-
Inst Trans
-
ROA
-56%
ROE
365%
ROC
-0.65%
Gross Margin
79%
Oper. Margin
-236%
Profit Margin
-246%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.46-32.0
52W High
+507.47%
52W Low
+1114.94%
RSI
72.95
Rel Volume
0.98
Avg Volume
1.63M
Volume
1.59M
Perf Week
4.38%
Perf Month
31.99%
Perf Quarter
193.82%
Perf Half Y
186.92%
-
-
-
-
Beta
0.915
-
-
Volatility
4.03%, 13.31%
Prev Close
0.36%
Price
194.39
Change
2.35%

Something similar

Top by Market Cap
AVGO
AMZ.DE
NVDA
0YXG.L
BRK-A
Top Correlated ETFs
SEAA.DE
AMEE.DE
EMDG.L
CGB.DE
SMN
Top Correlated Stocks
0JAV.L
ACAST.ST
FMFP
FORM
MLAEM.PA
Similar Market Cap
1528.TW
QLYS
603757.SS
IXJ
GATX

Company Profile

Healthcare Biotechnology
  • Volume Average 1.63M
  • Market Capitalization 4.05B
  • Employee 912
  • CEO Mr. William H. Lewis J.D., M.B.A.
  • Headquarters Bridgewater,NJ,US
  • IPO Date 2000-06-01
  • Website https://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.